Medicines | Horizonscan geneesmiddelen

Lisdexamfetamine ^IND Melatonine Molindone

ARI-0001 Brexucabtagene autoleucel ^IND Crisantaspase Obecabtagene autoleucel Ponatinib ^IND

Arimoclomol Masitinib Sodium phenylbutyrate / tauroursodeoxycholic acid

Cytarabine / daunorubicin (liposomaal) ^IND Decitabine / cedazuridine Eprenetapopt Glasdegib Imetelstat Ivosidenib Quizartinib

Acalabrutinib ^IND Axicabtagene ciloleucel ^IND Brexucabtagene autoleucel Crizotinib ^IND Epcoritamab Glofitamab

Ibrutinib

Mantle cell lymphoma (MCL), 1L. ^IND Extension of indication to include treatment with Imbruvica in combination with bendamustine and rituximab (BR) of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for autologous stem cell transplantation ^IND

Lisocabtagene maraleucel

Treatment of large B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), after at least two previous lines of treatments. Extension of indication to include treatment of adult patients with Second-line (2L) Transplant Intended (TI) Large B-Cell Lymphoma (LBCL) for Breyanzi. ^IND

Loncastuximab tesirine Pirtobrutinib Polatuzumab vedotin ^IND Tafasitamab Zamtocabtagene autoleucel Zanubrutinib ^IND

Dabigatran ^G Proteïne C ^IND

Dupilumab ^IND Masitinib Tezepelumab

Ceftobiprole Ceftolozane / tazobactam ^IND Citric acid / lactic acid / potassium bitartrate ^IND Clindamycin Dalbavancine ^IND Durlobactam / sulbactam Eravacycline Oritavancin diphosphate ^IND SER 109 Tebipenem

Avelumab ^IND

Durvalumab

Neo-adjuvant durvalumab met chemotherapie en adjuvant durvalumab voor behandeling in patiënten met spier invasieve blaaskanker. ^IND Unresectable locally advanced or metastatic urothelial cancer in combination with tremelimumab and chemotherapy ^IND

Enfortumab vedotin Erdafitinib Inbakicept Nivolumab ^IND

Etrasimod Etrolizumab ^IND Filgotinib ^IND Mirikizumab

Risankizumab

Skyrizi is geïndiceerd voor de behandeling van volwassen patiënten met matig tot ernstig actieve ziekte van Crohn die onvoldoende hebben gereageerd op, niet meer reageren op of intolerant waren voor conventionele behandeling of een biologische behandeling. ^IND Indicated for UC (collitis ulcerosa) with demonstrated intolerance or inadequate response to conventional therapy and tofacitinib (not a biologic) and one or more biologic therapies. ^IND

Teduglutide ^IND

Upadacitinib

Rinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. ^IND Extension of indication to include treatment of moderately to severely active Crohn's disease in adult patients. ^IND

Vedolizumab ^IND

Dabrafenib / trametinib

Abemaciclib ^IND Balixafortide Elacestrant Neratinib ^IND Olaparib ^IND Paclitaxel Palbociclib ^IND Pembrolizumab ^IND

Sacituzumab govitecan

For adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for advanced disease Eerder behandelde HR+/HER2- gemetastaseerde borstkanker ^IND

Tesetaxel

Trastuzumab deruxtecan

Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti HER2 based regimens. Extension of indication for Enhertu to include treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. ^IND Extension of indication to include treatment of unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or withing 6 months of completing adjuvant chemotherapy. Patients with hormone receptor positive (HR+) breast cancer must additionally have received or be ineligible for endocrine therapy. ^IND

Trastuzumab duocarmazine Tucatinib

Acalabrutinib

Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). Extension of the existing CLL indication to include combination treatment with venetoclax for previously untreated patients. ^IND

Ibrutinib ^IND Ublituximab

Zanubrutinib

Extension of indication to include treatment of adult patients with chronic lymphocytic leukaemia (CLL). ^IND Extension of indication to include treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one-prior anti-CD20-based therapy ^IND

Asciminib

Ensifentrine

APN01 Anakinra ^IND Baricitinib ^IND

Casirivimab / imdevimab

Treatment of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. Prevention of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg . Extension of indication to include treatment of COVID-19 in hospitalised patients in adults and adolescents aged 12 years and older weighing at least 40 kg for Ronapreve ^IND

Molnupiravir PF-07321332 / ritonavir

Remdesivir

Treatment of paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) or other non-invasive ventilation at start of treatment ^IND Treatment of paediatric patients (weighing at least 40kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19 ^IND

Tixagevimab / cilgavimab

Pre-expositie profylaxe van COVID-19 bij volwassenen en adolescenten van 12 jaar en ouder met een lichaamsgewicht van tenminste 40 kilo Evusheld is indicated for the treatment of adults and adolescents (aged 12 years and older weighing at least 40kg) with COVID‑19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID‑19. ^IND

Cemiplimab ^IND Lifileucel

Eflornithine / sulindac

Lumacaftor / ivacaftor ^IND

Donanemab Gantenerumab

Agomelatine ^IND Bupropion / dextromethorphan Esketamine ^IND

Bexagliflozine Dulaglutide ^IND Exenatide ^IND

Finerenon

Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. Extension of indication to include the treatment of chronic kidney disease (CKD) and for the prevention of cardiovascular (CV) events in adults with CKD (regardless of the stage of albuminuria) associated with type 2 diabetes ^IND

Insulin lispro ^IND Insuline Icodec Polyethylene glycol loxenatide Regulatoire T-cellen (TREGS) Sotagliflozine ^IND Teplizumab Tirzepatide

Fordadistrogene movaparvovec Givinostat Golodirsen Vamorolone Viltolarsen

Cannabidiol ^IND Fenfluramine ^IND Ganaxolone Lacosamide ^IND

Aflibercept

Diabetic macular edema ^BS Eylea is indicated in preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease. ^IND

Avacincaptad pegol

Faricimab

Treatment of neovascular (wet) age-related macular degeneration (nAMD). Treatment of visual impairment due to diabetic macular oedema (DME).

Lenadogene nolparvovec Pegcetacoplan Perfluorohexyloctane Phentolamine Polihexanide

Ranibizumab

Wet age-related macular degeneration (AMD). ^BS Treatment of neovascular age-related macular degeneration (AMD) Wet age-related macular degeneration (AMD) ^BS

Reproxalap Sepofarsen

Ibrexafungerp Oteseconazole Rezafungin

Doravirine / lamivudine / tenofovirdisoproxil ^IND Lenacapavir Raltegravir ^BS UB 421

Pembrolizumab ^IND Tislelizumab ^IND

Atogepant Dihydroergotamine Eptinezumab Lasmiditan Meloxicam / rizatriptan

Rimegepant

Acute treatment of migraine with or without aura in adults Preventive treatment of episodic migraine in adults who have at least 4 migraine attacks per month

Emicizumab ^IND Eptacog alfa (activated) ^BS Eptacog beta (activated) Etranacogene dezaparvovec Fidanacogene elaparvovec Valoctocogene roxaparvovec

Axicabtagene ciloleucel ^IND Hypericin Lacutamab Mosunetuzumab Parsaclisib Tisagenlecleucel-T ^IND

Baloxavir marboxil ^IND Cefepime / Enmetazobactam Fluticasone propionate

Cabozantinib ^IND Ilixadencel Lenvatinib ^IND

Pembrolizumab

Extension of indication for Keytruda to include in combination with lenvatinib first line treatment of adults with advanced renal cell carcinoma (RCC). ^IND Keytruda as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions. ^IND

Tivozanib ^IND

Bempedoic acid Evinacumab

Atezolizumab ^IND

Durvalumab

Durvalumab (+/- bevacizumab) in combinatie met TACE in patiënten met locoregionale HCC. ^IND Extension of indication to include IMFINZI in combination with tremelimumab for the treatment of adults with unresectable hepatocellular carcinoma (uHCC). ^IND

Lenvatinib ^IND Pembrolizumab ^IND Tremelimumab ^IND

Arachidyl amido cholanoic acid Maralixibat Seladelpar

Adagrasib Amivantamab Atezolizumab ^IND Avelumab ^IND Cabozantinib ^IND Capmatinib

Cemiplimab

Libtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC. ^IND Extension of indication to include LIBTAYO in combination with platinum‐based chemotherapy for the first-line treatment of adult patients with locally advanced NSCLC who are not candidates for definitive chemoradiation or metastatic NSCLC with no EGFR, ALK or ROS1 aberrations, independen of PD-L1 expression. ^IND

Durvalumab

Extension of indication to include first-line treatment, with Imfinzi in combination with tremelimumab and platinum-based chemotherapy, of adults with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. ^IND Non-small cell lung cancer (NSCLC) stage IV, in combination with chemo, 1L. ^IND 1L advanced NSCLC ^IND Completely resected NSCLC ^IND Lokaal gevorderd, niet-resectabel NSCLC (stadium III) ^IND Limited stage small cell lung cancer (LS-SCLC) following concurrent platinum-based chemotherapy and radiation therapy in combination with Tremelimumab. ^IND

Ensartinib Lenvatinib ^IND Lurbinectedin Mobocertinib Nivolumab ^IND OSE-2101 Pembrolizumab ^IND Pralsetinib Selpercatinib ^IND Sintilimab Sotorasib Tepotinib

Tislelizumab

2L NSCLC (mono): As monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults 1L non-squamous NSCLC (combi): In combination with pemetrexed and platinum-containing chemotherapy for the first-line treatment of locally advanced or metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations 1L squamous NSCLC (combi): In combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of locally advanced or metastatic squamous NSCLC in adults

Toripalimab Trastuzumab deruxtecan ^IND Tremelimumab Trilaciclib

Benralizumab ^IND Gefapixant Nintedanib ^IND Pamrevlumab Pirfenidone ^IND Riociguat ^IND tocilizumab ^IND

ALXN1840 Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A gene Avalglucosidase alfa Bardoxolone Methyl Cipaglucosidase alfa / miglustat Empagliflozine ^IND Fexapotide Fezolinetant Fosdenopterin Leriglitazone Liraglutide ^IND Lixivaptan Lonafarnib Octreotide Olenasufligene relduparvovec Olipudase alfa Palovarotene Pariglasgene brecaparvovec Pegunigalsidase alfa RGX-121 Reloxaliase Somapacitan Somatrogon Sparsentan TransCon PTH (palopegteriparatide)

Belantamab mafodotin ^IND Carfilzomib ^IND Ciltacabtagene autoleucel

Daratumumab

Multipel myeloom frontline behandeling in combinatie met VRd voor patiënten die niet in aanmerking komen voor een ASCT. ^IND Smouldering multipel myeloom. ^IND Multipel myeloom frontline behandeling in combinatie met VRd voor patiënten die in aanmerking komen voor een ASCT. ^IND

Elranatamab Idecabtagene vicleucel

Isatuximab

Sarclisa is indicated in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ^IND In Combination With Bortezomib, Lenalidomide and Dexamethasone (Isa VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant. ^IND

Ixazomib ^IND Melphalan flufenamide ^IND Pomalidomide ^IND Selinexor ^IND Teclistamab Thalidomide ^G Venetoclax ^IND Zevorcabtagene autoleucel

Dimethyl fumarate ^IND Natalizumab ^BS

Teriflunomide

Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). ^G Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). ^G

Ublituximab

Bidridistrogene xeboparvovec Dantroleen ^G Daxibotulinumtoxine A Deoxythymidine / deoxycytidine Di-deuterated ethyl linoleate Efgartigimod Omaveloxolone Ravulizumab ^IND Rozanolixizumab Satralizumab ^IND Zilucoplan

Bomedemstat Momelotinib Navitoclax

Selumetinib Surufatinib

Cannabidiol Clazosentan Eladocagene exuparvovec Inebilizumab Ravulizumab ^IND Satralizumab Tiratricol Tominersen Trofinetide Vutrisiran

Afamitresgene autoleucel Dostarlimab Durvalumab ^IND Efbemalenograstim alfa Erdafitinib Futibatinib Glucarpidase Infigratinib Ivosidenib Jodium (131I) omburtamab

Lenvatinib

Extension of indication to include lenvatinib in combination with pembrolizumab for the treatment of adult patients with advanced endometrial carcinoma (EC) who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation ^IND Advanced or Recurrent Endometrial Cancer (1L) in combination with pembrolizumab. ^IND

Lipegfilgrastim ^IND NY-ESO-1 autologous engineered TCR-T cells Nirogacestat

Pembrolizumab

Extension of indication to include pembrolizumab in combination with lenvatinib for the treatment of advanced endometrial carcinoma in adults who have disease progression following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation. ^IND Keytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD‑L1 with a CPS ≥ 1. ^IND Keytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 10. ^IND Keytruda as monotherapy is indicated for the treatment of the following MSI‑H or dMMR tumours in adults with: unresectable or metastatic colorectal cancer after previous fluoropyrimidine‑based combination therapy; advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum‑containing therapy in any setting and who are not candidates for curative surgery or radiation; unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. ^IND indication for treatment with pembrolizumab plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma ^IND

Selinexor ^IND Sodium thiosulfate Tebentafusp

Tislelizumab

2L locally advanced or metastatic ESCC (esophageal squamous-cell carcinoma) 1L locally advanced or metastatic ESCC (esophageal squamous-cell carcinoma)

Avapritinib

Advanced systemic mastocytosis (AdvSM). AYVAKYT is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL), after at least one systemic therapy. ^IND Non-advanced systemic mastocytosis ^IND

Baricitinib

Systemic lupus erythematosus ^IND Extension of indication to include treatment of severe alopecia areata in adult patients for Olumiant. ^IND

Berotralstat Budesonide modified released capsule Canakinumab ^IND Coacillium topical Dupilumab ^IND FCR 001 Leniolisib Marnetegragene autotemcel Mavorixafor Ritlecitinib Sizavaleucel Sutimlimab Voclosporin Vonoprazan

Lenzilumab

Angiotensin II Dapagliflozine ^IND Etripamil Icosapent ethyl Macitentan ^IND Macitentan / tadalafil Mavacamten Neoatricon (dopamine) Omecamtiv mecarbil Rexlemestrocel-L Rilonacept Sotagliflozine ^IND Sotatercept Tadalafil ^IND Treprostinil ^G Valsartan / sacubutril ^IND

Abaloparatide

Treatment of osteoporosis in postmenopausal women at increased risk of fracture Treatment of osteoporosis.

Alpelisib Burosumab ^IND Corifollitropin alfa ^IND Ganirelix ^G Linzagolix ^IND Ospemifene ^IND Pegzilarginase

Semaglutide

For weight management in people with obesity or who are overweight and have other related conditions. Extension of indication to include treatment of adolescents for weight management for Wegovy. ^IND

Setmelanotide

Imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above. IMCIVREE is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet‑Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above. ^IND

Vosoritide

Crizanlizumab Danicopan Daprodustat Eculizumab ^BS Efgartigimod Eltrombopag ^IND Eptacog alfa ^IND Exagamglogene autotemcel Ferumoxytol Horse anti-human T lymphocyte immunoglobulin Iptacopan Luspatercept ^IND Methoxy polyethylene glycol-epoetin beta ^IND Mitapivat Mozafancogene autotemcel Pegcetacoplan

Ravulizumab

Treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) in patients with haemolysis with clinical symptom(s) indicative of high disease activity and in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. Uitbreiding van de behandeling naar pediatrische patiënten met een lichaamsgewicht van 10kg of meer met paroxismale nachtelijke hemoglobinurie (PNH):- bij patiënten met hemolyse met klinische symptomen die wijzen op een hoge ziekteactiviteit.- bij patiënten die klinisch stabiel zijn nadat ze ten minste de afgelopen 6 maanden behandeld zijn met eculizumab. ^IND

UM171 Vadadustat Voxelotor

Dexmedetomidine

Dostarlimab ^IND Mirvetuximab soravtansine Rucaparib ^IND

Bupivacaine Buprenorfine ^IND Fasinumab SDN037

Lotilaner

Levodopa / carbidopa

Darolutamide ^IND Degarelix ^G Enzalutamide ^IND Gozetotide Leuprolide mesylate Lutetium (177lu) vipivotide tetraxetan Masitinib Niraparib / abiraterone Olaparib ^IND Pembrolizumab ^IND Relugolix Talazoparib ^IND

Anifrolumab Baricitinib ^IND

Bimekizumab

Extension of indication to include Bimzelx, alone or in combination with conventional disease-modifying antirheumatic drugs (cDMARDs), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more DMARDs. ^IND Extension of indication to include treatment of adults with active axial spondyloarthritis (axSpA), including non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS, radiographic axial spondyloarthritis) ^IND

Cyclobenzaprine hydrochloride Sarilumab ^IND Secukinumab ^IND Tocilizumab ^BS Upadacitinib ^IND

Risdiplam

5q SMA in patients 2 months of age and older, with a clinical diagnosis of Type 1, Type 2 or Type 3 SMA or with one to four SMN2 copies. Extension of indication to include treatment of patients below 2 months of age. ^IND

Roluperidon

Darleukin fibromun Ipilimumab ^IND Lenvatinib ^IND Lifileucel Nivolumab ^IND

Pembrolizumab

1L treatment with pembrolizumab for advanced melanoma, in combination with lenvatinib. ^IND KEYTRUDA as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC or III melanoma and who have undergone complete resection ^IND

Relatlimab / nivolumab Tavokinogene telseplasmid

Baricitinib ^IND Beremagene geperpavec Berkenschorsextract Concentrate of proteolytic enzymes enriched in bromelain ^IND Dabocemagene autoficel Deucravacitinib Difelikefalin

Dupilumab

Dupixent is geïndiceerd bij kinderen van 6 maanden tot 6 jaar met ernstige atopische dermatitis die in aanmerking komen voor systemische behandeling. ^IND Dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy. ^IND

Lebrikizumab Regenerative Skin Tissue Roflumilast topicaal Ruxolitinib phosphate Secukinumab ^IND Sirolimus ^G Spesolimab Tralokinumab ^IND

Daridorexant JZP-258 Natriumoxybaat controlled release

Pitolisant

Ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by, or who have not tolerated, OSA primary therapy, such as continuous positive airway pressure (CPAP). Extension of indication to include treatment of narcolepsy with or without cataplexy in adolescents and children from the age of 6 years. ^IND

Narsoplimab Omidubicel Plerixafor ^G Ruxolitinib ^IND Tabelecleucel Treosulfan ^IND UM171

Catumaxomab

Pembrolizumab

indication for treatment with pembrolizumab in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil [FP regimen] or oxaliplatin combined with capecitabine [CAPOX regimen]) in the treatment of HER2 negative advanced gastric or GEJ adenocarcinoma in adult participants. ^IND indication for treatment with pembrolizumab plus trastuzumab in combination with standard of care chemotherapy for adults with HER2 positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma ^IND Treatment in the neoadjuvant or adjuvant setting of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma. ^IND

Ripretinib Tislelizumab ^IND Trastuzumab deruxtecan ^IND Zolbetuximab

Cabozantinib ^IND

Pralsetinib

Gavreto is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with Tyrosine Kinase inhibitors and not previously treated with a RET inhibitor. ^IND Gavreto is indicated for the treatment of adults and pediatric patients 12 years of age and older with locally advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with Tyrosine kinase inhibitors and not previously treated with a RET inhibitor. ^IND

Selpercatinib

1L treatment advanced or metastatic RET fusion-positive thyroid cancer (TC) ^IND Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC) ^IND

Selpercatinib ^IND

Diazoxide choline (controlled-release tablet) Levonorgestrel ^G Linzagolix Lonapegsomatropin Lumasiran Mirabegron ^IND Olopatadine / mometasone Pirfenidone ^G Relugolix ^IND Relugolix / estradiol / norethisteronen Sofpironium bromide Vibegron

Bizalimogene ralaplasmid Bulevirtide

Letermovir

Extension of Letermovir From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant ^IND Letermovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients ^IND

Lonafarnib ^IND Maribavir Nirsevimab Posoleucel Tenofovir alafenamide ^IND

Published on 7 December 2022

ADHD

ALL

ALS

AML / MDS

Aggressive non-Hodgkin’s lymphoma

Ibrutinib

Lisocabtagene maraleucel

Antithrombotic medications

Asthma

Bacterial infections

Bladder cancer

Durvalumab

Bowel diseases

Risankizumab

Upadacitinib

Brain cancer

Breast cancer

Sacituzumab govitecan

Trastuzumab deruxtecan

CLL

Acalabrutinib

Zanubrutinib

CML

COPD

COVID-19

Casirivimab / imdevimab

Remdesivir

Tixagevimab / cilgavimab

Cervical cancer

Colon cancer

Cystic fibrosis

Dementia

Depression

Diabetes

Finerenon

Duchenne

Epilepsy

Eye disorders

Aflibercept

Faricimab

Ranibizumab

Fungal infections

HIV

Head and neck cancer

Headache

Rimegepant

Hemostasis promoting medication

Indolent non-Hodgkin’s lymphoma

Infectious diseases other

Kidney cancer

Pembrolizumab

Lipid-lowering medications

Liver cancer

Durvalumab

Liver diseases

Lung cancer

Cemiplimab

Durvalumab

Tislelizumab

Lung diseases other

Metabolic diseases

Multiple Myeloma

Daratumumab

Isatuximab

Multiple sclerosis

Teriflunomide

Muscular diseases other

Myeloproliferative disorders

Neuroendocrine cancer

Neurological disorders other

Oncology other

Lenvatinib

Pembrolizumab

Tislelizumab

Other chronic immune diseases

Avapritinib

Baricitinib

Other hematology

Other medication for cardiovascular diseases